PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470)

  • Authors:
    • O SARTOR
  • View Affiliations

  • Published online on: November 1, 1995     https://doi.org/10.3892/or.2.6.1101
  • Pages: 1101-1102
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A 61-year-old man with progressive prostate cancer after initial hormonal therapy was treated with TNP-470, an experimental agent with potent antiangiogenesis properties. During the period of TNP-470 treatment, the concentration of serum prostate-specific antigen (PSA) rapidly increased from 28.4 to 89.9 ng/ml. After termination of TNP-470 therapy, the concentration of PSA decreased from 89.9 to 10.3 ng/ml. This pattern of PSA change was previously unanticipated and may eventually provide additional insight into the pharmacological actions of TNP-470.

Related Articles

Journal Cover

November 1995
Volume 2 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
SARTOR O: PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470). Oncol Rep 2: 1101-1102, 1995
APA
SARTOR, O. (1995). PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470). Oncology Reports, 2, 1101-1102. https://doi.org/10.3892/or.2.6.1101
MLA
SARTOR, O."PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470)". Oncology Reports 2.6 (1995): 1101-1102.
Chicago
SARTOR, O."PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470)". Oncology Reports 2, no. 6 (1995): 1101-1102. https://doi.org/10.3892/or.2.6.1101